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Abstract
Objective. Unwarranted variation in clinical practice is a target for quality improvement in health care, but there is no
consensus onhow to identify suchvariationor to assess the potential valueof initiatives to improvequality in these areas. This
study illustrates the use of a triple test, namely the comparative analysis of processes of care, costs and outcomes, to identify
and assess the burden of unwarranted variation in clinical practice.
Methods. Routinely collected hospital andmortality datawere linked for patients presentingwith symptoms suggestive
of acute coronary syndromes at the emergency departments of four public hospitals in South Australia. Multiple regression
models analysed variation in re-admissions and mortality at 30 days and 12 months, patient costs and multiple process
indicators.
Results. After casemix adjustment, an outlier hospital with statistically signiﬁcantly poorer outcomes and higher costs
was identiﬁed. Key process indicators included admission patterns, use of invasive diagnostic procedures and length of stay.
Performance varied according to patients’ presenting characteristics and time of presentation.
Conclusions. The joint analysis of processes, outcomes and costs as alternative measures of performance inform the
importance of reducing variation in clinical practice, as well as identifying speciﬁc targets for quality improvement along
clinical pathways. Such analyses could be undertaken across a wide range of clinical areas to inform the potential value and
prioritisation of quality improvement initiatives.
What is known about the topic? Variation in clinical practice is a long-standing issue that has been analysed frommany
different perspectives. It is neither possible nor desirable to address all forms of variation in clinical practice: the focus should
be on identifying important unwarranted variation to inform actions to reduce variation and improve quality.
What does this paper add? This paper proposes the comparative analysis of processes of care, costs and outcomes for
patients with similar diagnoses presenting at alternative hospitals, using linked, routinely collected data. This triple test of
performance indicators extracts maximum value from routine data to identify priority areas for quality improvement to
reduce important and unwarranted variations in clinical practice.
What are the implications for practitioners? The proposed analyses need to be applied to other clinical areas to
demonstrate the general application of the methods. The outputs can then be validated through the application of quality
improvement initiatives in clinical areas with identiﬁed important and unwarranted variation. Validated frameworks for
the comparative analysis of clinical practice provide an efﬁcient approach to valuing and prioritising actions to improve
health service quality.
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Variation in clinical practice remains a widely acknowledged
barrier to the equitable and efﬁcient provision of health care.1
Some variation is warranted, reﬂecting heterogeneity in the
clinical symptoms and preferences of individual patients, but
there is also unwarranted variation,which results in the inefﬁcient
use of scarce healthcare resources. Unwarranted variation has
been broadly deﬁned as reﬂecting ‘the limits of professional
knowledge and failures in its application’.2 Quality improvement
to reduce unwarranted variation in clinical practice is not a trivial
task,3 and so healthcare providers should focus on priority areas,
in which expected net beneﬁts are greatest.
The identiﬁcation of important and unwarranted variation in
clinical practice necessitates some form of comparative assess-
ment of hospital performance. Australian Commission on Safety
and Quality in HealthCare (ACSQHC) has published Clinical
Care Standards for a range of key clinical areas,4 with associated
sets of process indicators to assist quality improvement. A
limitation of process indicators is the focus on components of
care pathways that are measurable. Important aspects of a care
pathway may not be measurable because of data system limita-
tions, as well as because of the non-deterministic and qualitative
nature of the processes being measured.5 This means process
indicators alone provide only a partial analysis of quality.
The ACSQHC is also promoting the use of hospital mortality
indicators as a screening tool to identify high and low performing
areas of clinical activity.6 Lilford et al. cite the poor correlation
between outcomes and quality7 while noting that the problems
associated with outcome measures are reduced when they are
not used to judge performance, but to inform improvement in a
non-punitive manner.
Alternatively, activity-based funding aims to inform health-
care improvements through analyses of cost differences in the
provision of similar services. The Independent Hospital Pricing
Authority is developing methods to incorporate measures of
qualitywithin an activity-based funding framework, but currently
no adjustments are made for safety and quality.8
As the above examples indicate, the alternative forms of
performance measurement are generally considered in isolation.
This paper presents a case study application of a triple test to
screen for important variations in processes of care, costs and
outcomes for patients presenting with symptoms suggestive of
acute coronary syndromes (ACS) at four large public hospitals
in South Australia (SA).
Methods
Routinely collected hospital data were used to inform compar-
ative analyses of processes of care, costs and outcomes for
patients presenting at the emergency department (ED) with
symptoms suggestive of ACS. The following sections describe
the deﬁnition of the eligible population, the data sources and
the data analysis methods.
Eligible population
The eligible population comprised all patients attending the ED of
one of the four main public hospitals in SA in the year to 30 June
2010 with an ED diagnosis of either chest pain (International
Classiﬁcations of Diseases (ICD)-10 code R07), unstable angina
(ICD-10 code I20), or myocardial infarction (MI; ICD-10 code
I21) and who received at least one troponin assay (a diagnostic
indicator of cardiac muscle injury) during their hospital episode.
Data sources
The four study hospitals each maintain a suite of local data
warehouses containing comprehensive patient-level information
that describes key procedures, pathology test results, movement
between hospital departments and wards etc., as well as auto-
mated links to population-based mortality data. These local
systems have comparable nomenclature and collection practices,
and are collated by the state health department in the form of a
single, state-wide repository.
Separate administrative data, submitted to the state health
department for every in-patient separation at all public and
private SA hospitals, were available from 2003 to June 2011.
These data include variables such as age, gender and postcode
of normal residence (to inform Socioeconomic Indexes for Areas
(SEIFA) scores), as well as comorbidities.
Probabilistic data linkage methods using name, gender and
date of birth were used to group public hospital separations
by patient. Private hospital separations were assigned to these
groups on the basis of matching Medicare numbers.
Comorbidities were coded on the basis of principal and
additional diagnoses in the 12 months preceding the index ED
presentation.9 The cost of the index hospital episode was esti-
mated for every eligible patient, representing both the ED and
in-patient component (for admitted patients). Detailed patient-
level costs were available for all in-patient separations, which
were estimated by each hospital and submitted to the state health
department. Outcomes were speciﬁed as a related re-admission
(for unstable angina, MI or stroke) or mortality within 30 days
and within 12 months.
Variables relating to the process of care were reviewed with
clinical experts to select a set of process variables with the greatest
potential for insight into variations in healthcare costs and patient
outcomes across hospitals. The selected process indicators in-
cluded the proportion of presenting patients admitted to hospital,
the time to admission (i.e. length of stay (LOS) in the ED), the
proportion of patients undergoing an invasive diagnostic proce-
dure and the proportion of those who went on to receive an
invasive management procedure, as well as total in-patient LOS
for admitted patients.
Data analysis
To identify variation between the hospitals, separate multiple
regression models were ﬁtted to the data for each of the speciﬁed
cost, outcome and process of care dependent variables. Binary
hospital attendance covariates were used to test for hospital
effects, with hospital interaction terms used to identify patient
subgroups that may be driving variation observed at the aggregate
hospital level. Other model covariates were selected from patient-
level variables (age, gender, troponin test result (positive or
negative), SEIFA score), as well as a wide range of binary
comorbidity and recent hospital admission variables. Interactions
between key patient-level covariates were also tested.
For binary dependent variables, logistic regression models
were ﬁtted. Model speciﬁcation was tested using the link test.
Goodness-of-ﬁt was assessed by the Hosmer Lemeshow test,
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and the area under the receiver operating characteristic (ROC)
curve. For the continuous dependent variables, generalised linear
models (GLMs) were ﬁtted. Model speciﬁcation was tested
using the link test. Diagnostic tests included the modiﬁed Park
test (for the GLM family) and the Pearson correlation test,
the Pregibon link test and the modiﬁed Hosmer Lemeshow
test (for the GLM link),10 as well as visual inspection of the
residuals.
For each ﬁtted model, the mean covariate values were applied
to generate predicted outputs for each hospital at an aggregate
level and for each patient subgroup (as deﬁned by the hospital
interaction terms in each model). Relative risks (RRs) were
estimated for binary dependent variables and mean differences
were determined for continuous dependent variables. To repre-
sent the uncertainty around the mean results, 1000 bootstrap
samples of the dataset were generated, stratiﬁed by hospital. The
regression models were reﬁtted for each bootstrap sample, and
outputs generated for a hypothetical patient with mean values
for each of the covariates included in the models (e.g. mean age,
proportion of male patients etc.). The bootstrap outputs informed
conﬁdence intervals around each cost, outcome and process
variable for the aggregate and subgroup analyses. Using the joint
cost and outcomes outputs of the bootstrap analysis, cost-effec-
tiveness acceptability curves were generated to represent the
probability of each hospital being the benchmark performer
across a range of threshold values.
Ethics committee approval was granted by the SA Health
Human Research Ethics Committee.
Results
The analysis included 7950 eligible patients, ranging from 1527
patients at Hospital 2 to 2368 patients at Hospital 3. Table 1
describes the key characteristics of the patients presenting at the
comparator hospitals. There were statistically signiﬁcant differ-
ences in some key baseline characteristics, including age, socio-
economic status, objective risk markers (troponin test) and
existing circulatory conditions and diabetes.
In adjusting for differences in baseline characteristics, all the
ﬁtted regression models for the alternative process of care, cost
and patient outcome dependent variables passed the a priori
speciﬁed tests for goodness-of-ﬁt and model speciﬁcation. The
following sections describe the model outputs for patient out-
comes, costs and processes of care, respectively.
Patient outcomes
Outcome events were analysed at 30 days and 12 months, with
regard to hospital admissions for cardiovascular events and
mortality. Table 2 describes event rates at each hospital, as well
as RRs compared with the hospital with the highest event rates
(Hospital 2). Across all patients, the 30-day event rate ranged
from 0.9% to 2.1%. The RRs ranged from 0.45 to 0.83, but the
RR was only statistically signiﬁcantly <1 at Hospital 1. The
subgroup analysis, by age, suggests that Hospital 1 is achieving
particularly improved outcomes in younger patients.
At 12 months, the event rate for re-admissions or mortality
was signiﬁcantly higher at Hospital 2 compared with all other
hospitals. The mean RRs ranged from 0.64 to 0.72. Separate
analysis of mortality and re-admissions at 12 months showed
increased event rates for both outcomes at Hospital 2, with all
RRs either at or approaching statistical signiﬁcance.
Index presentation costs
Table 3 presents differences in in-patient costs associated with
the index chest pain presentations across the study hospitals. The
cost per presenting patient is reported, based on the proportion
of patients who were admitted at each hospital. Across all
patients, Hospital 2 reported the highest standardised costs per
presenting patient, which were over A$600 more per patient
than atHospitals 1 and 4 (and signiﬁcantly higher). Over the 1527
patients presenting at Hospital 2, these additional costs sum to
almost A$1million every year at Hospital 2.
Costs at Hospital 2 are particularly high in the subgroup of
presenting patients with prior experience of a circulatory condi-
tion, which may be linked to the increased in-patient admission
Table 1. Care setting and patient characteristics by hospital
SEIFA, Socioeconomic Indexes for Areas (1 = lowest decile); ACS, acute coronary syndromes; COPD, chronic obstructive
pulmonary disease. Values italicised have units as proportions
Hospital 1 Hospital 2 Hospital 3 Hospital 4 P-value
Teaching status Yes Yes Yes Yes
Total no. beds 590 310 650 320
Interventional cardiac service Yes Yes Yes Yes
Annual suspected ACS points 1997 1527 2368 2058
Mean (± s.d.) age (years) 60.2 ± 17.5 62.5 ± 16.8 59.1 ± 18.2 57.9 ± 16.2 <0.001
Proportion Male 0.54 0.53 0.53 0.54 0.768
Mean (± s.d.) SEIFA decile 5.4 ± 2.6 4.0 ± 2.4 6.0 ± 2.6 2.6 ± 2.0 <0.001
Positive troponin test result 0.17 0.13 0.12 0.11 <0.001
Existing circulatory disorder 0.37 0.33 0.37 0.33 0.002
Cancer 0.03 0.03 0.03 0.02 0.189
COPD 0.03 0.03 0.03 0.03 0.706
Renal disease 0.07 0.08 0.09 0.07 0.398
Diabetes 0.07 0.06 0.09 0.10 <0.001
Dementia or Alzheimer’s disease 0.01 0.02 0.01 0.01 0.716
After-hours presentation 0.61 0.62 0.59 0.58 0.082
Weekend presentation 0.24 0.25 0.23 0.24 0.636
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rate for this patient group at Hospital 2. Conversely, Hospital 3
has signiﬁcantly increased costs in the subgroup of patients
without an existing circulatory condition.
Figure 1 combines the above analyses of costs and patient
outcomes in the form of cost-effectiveness acceptability planes,
which represent the probability that each hospital is the most
cost-effective (and thus the benchmark) hospital at different
equivalent monetary values for avoiding admissions and mortal-
ity at 12 months (as represented on the x-axes). As an example,
if we assign an equivalent monetary value of A$100 000 to
avoiding a death at 12 months and a value of A$50 000 to
avoiding an admission, Hospitals 1, 2, 3 and 4 have probabilities
of being the most cost-effective hospital of 30%, 0%, 32%, and
38%, respectively. It is clear that the choice of the benchmark
hospital varies signiﬁcantly between Hospitals 1, 3 and 4 accord-
ing to the values associated with the avoidance of mortality and
hospital admissions. However, it is apparent that there is a very
small likelihood that Hospital 2 is the benchmark hospital, which
is consistent with the signiﬁcantly increased costs and outcome
events at Hospital 2 (Tables 2, 3).
Process indicators
Table 4 presents comparative data on three process indicators
after adjustment for observed confounders, namely the proportion
of presenting patients admitted as an in-patient, undergoing an
invasive revascularisation procedure (e.g. percutaneous coronary
intervention (PCI)) and undergoing a PCI following an invasive
diagnostic procedure (angiography). Results for Hospitals 1, 3
and 4 are reported relative to Hospital 2.
Across all patients, Hospital 2 admitted the lowest proportion
of presenting patients (67%), which was signiﬁcantly lower
than for all the other hospitals. Subgroup analyses indicated
the lower aggregate admission rate at Hospital 2 was driven by
a particularly low admission rate for patients with no existing
circulatory condition and a negative troponin test result on
presentation. The admission rates at the other hospitals were
between 27% and 41% higher in this group.
The proportion of patients undergoing PCI was signiﬁcantly
lower at Hospital 2 compared with Hospitals 1 and 3. No
consistent pattern was observed across the subgroups, indicating
variation in practice across and within hospitals; for example,
Hospital 1 had higher PCI rates during the week, whereas
Hospital 3 had higher PCI rates for patients with positive
troponin test results.
The highest proportion of patients undergoing angiography
followed by PCI was at Hospital 2 (34%), compared with
between 15% and 25% at the other hospitals. Given the lower
aggregate rate of PCI at Hospital 2, this result is driven by a low
rate of angiography. Subgroup analyses showed that Hospital 2
had a higher conversion rate from angiography to PCI regardless
of initial troponin test result or day of presentation.
Table 5 reports differences in two LOS variables. For patients
admitted as an in-patient, themean time to admissionwas shortest
at Hospital 3 by between 3.9 and 5.5 h. There was less variation
between the other hospitals, and the timings did not vary greatly
by patient subgroup. Hospital 4 reported the shortest mean in-
patient LOS. Hospitals 2 and 3 reported signiﬁcantly longer LOS
for patients with a positive troponin test.
Discussion
Electronic hospital data systems collect signiﬁcant amounts of
data describing the processes of care experiencedwithin hospital,
as well as the resources used during hospital encounters. Modern
data systems also better facilitate the linkage of data across the
healthcare system, so that patient outcomes with regard to re-
admissions and mortality beyond discharge can be measured.
This paper has presented comparative analyses of processes of
care, costs and patient outcomes using routinely collected data
Table 3. Index in-patient costs, per presenting patient
Statistically signiﬁcant differences are bolded. Circ., circulatory condition; out-hrs, out-of-hours presentation; in-hrs, in-hours presentation; CI, conﬁdence
interval
Patient group No. patients Mean cost Mean cost minus cost at Hospital 2 (A$; 95% CI)
Hospital 2 (A$) Hospital 1 Hospital 3 Hospital 4
All patients 7950 3341 –669 (–1121, –235) –148 (–525, 232) –618 (–940 to –292)
Existing circ., out-hrs 1706 5855 –1303 (–2249, –360) –986 (–1718, –223) –1526 (–2318 to –761)
No existing circ., out-hrs 1082 1680 –639 (–964, –337) 342 (18, 636) –141 (–375 to 63)
Existing circ., in-hrs 3050 5684 –601 (–1563, 390) –691 (–1500, 70) –1228 (–2035 to –457)
No existing circ., in-hrs 2112 1541 125 (–307, 600) 637 (304, 937) 103 (–140 to 317)
Table 2. Outcomes at 30 days and 12 months
*Statistically signiﬁcant differences are bolded. Pr(Event), probability of death or hospital admission for unstable angina,
myocardial infarction or stroke; RR, relative risk; CI, conﬁdence interval
Outcome Pr(Event) RR vs Hospital 2 (95% CI)*
Hospital 2 Hospital 1 Hospital 3 Hospital 4
30 day re-admission or death 0.021 0.45 (0.24–0.72) 0.78 (0.54–1.12) 0.83 (0.54–1.19)
12 month re-admission or death 0.072 0.64 (0.51–0.79) 0.67 (0.50–0.86) 0.72 (0.58–0.90)
12 month mortality 0.024 0.73 (0.48–1.04) 0.58 (0.35–0.89) 0.69 (0.44–1.07)
12 month re-admission 0.048 0.60 (0.44–0.79) 0.72 (0.51–0.95) 0.75 (0.57–0.98)
















































































































































Fig. 1. Cost-effectiveness acceptability plots for Hospitals 1–4 showing the probability that each hospital (prhosp) is the benchmark cost-effective hospital
for alternative monetary equivalent values for the avoidance of mortality and re-admission within 12 months of an eligible index event.
Table 4. Processes: probability of being admitted and probability of undergoing a percutaneous coronary intervention (PCI)
given an angiogram
*Statistically signiﬁcant differences are bolded. Pr(Event), probability of event shown; circ., circulatory condition; weekend, weekend
presentation; weekday, weekday presentation; RR, relative risk; CI, conﬁdence interval
No. patients Pr(Event) RR vs Hospital 2 (95% CI)*
Hospital 2 Hospital 1 Hospital 3 Hospital 4
Pr(Admitted as an in-patient)
All patients 7950 0.67 1.16 (1.10–1.22) 1.07 (1.00–1.13) 1.07 (1.01–1.13)
Troponin positive, existing circ. 842 0.97 1.01 (0.99–1.02) 0.98 (0.94–1.00) 0.98 (0.94–1.00)
Troponin positive, no existing circ. 216 0.77 1.14 (1.06–1.26) 1.01 (0.89–1.15) 1.02 (0.90–1.16)
Troponin negative, existing circ. 1946 0.87 1.02 (0.97–1.07) 0.99 (0.94–1.04) 0.99 (0.94–1.04)
Troponin negative, no existing circ. 4946 0.44 1.41 (1.30–1.56) 1.27 (1.16–1.39) 1.27 (1.16–1.39)
Pr (Undergo PCI)
All patients 7950 0.11 1.46 (1.20–1.75) 1.30 (1.08–1.56) 0.98 (0.80–1.19)
Troponin positive, weekend 279 0.43 1.00 (0.77–1.28) 1.44 (1.18–1.79) 1.26 (1.03–1.55)
Troponin positive, weekday 779 0.38 1.31 (1.05–1.66) 1.50 (1.20–1.89) 1.29 (1.04–1.62)
Troponin negative, weekend 1632 0.10 1.09 (0.77–1.47) 1.22 (0.99–1.48) 0.92 (0.73–1.13)
Troponin negative, weekday 5260 0.08 1.66 (1.31–2.06) 1.23 (0.99–1.50) 0.92 (0.73–1.14)
Pr (PCI/angiography)
All patients 7950 0.34 0.43 (0.30–0.56) 0.74 (0.54–0.99) 0.66 (0.47–0.88)
Troponin positive, weekend 279 0.62 0.49 (0.31–0.73) 0.50 (0.30–0.75) 0.44 (0.27–0.67)
Troponin positive, weekday 779 0.45 0.50 (0.36–0.67) 0.60 (0.39–0.85) 0.85 (0.62–1.12)
Troponin negative, weekend 1632 0.45 0.40 (0.23–0.66) 0.64 (0.37–1.03) 0.35 (0.19–0.59)
Troponin negative, weekday 5260 0.29 0.44 (0.28–0.62) 0.86 (0.56–1.21) 0.82 (0.54–1.16)
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to inform the potential value of quality improvement around the
diagnosis and management of suspected ACS.
Statistically signiﬁcant casemix-adjusted differences were
observed in mean in-patient costs (up to A$669 extra per pre-
senting patient) and 30-day and 12-month cardiovascular or
mortality event rates (up to 122% and 56%, respectively) across
providers. The analysis of costs and patient outcomes did not
identify a single benchmark hospital, but rather identiﬁed an
apparent outlier hospital that incurred higher costs and poorer
patient outcomes than the other hospitals.
Looking at the processes of care, the outlier hospital had the
lowest in-patient admission rate, which was driven by much
reduced admission rates for patients with negative troponin tests
and no existing circulatory condition on presentation. This sug-
gests that admission decisions for this seemingly low-risk patient
subgroup may be reviewed. The outlier hospital made the least
use of invasive management options (PCI), but a higher propor-
tion of patients undergoing an invasive diagnostic procedure
(angiography) proceeded to PCI. Interpreting this ﬁnding in
conjunction with the poorer outcomes observed at this hospital
implies high speciﬁcity (few false positives), but low sensitivity
(more false negatives) with regard to the use of angiography.
Both areas of process variation may be affected by variations in
capacity (e.g. access to in-patient beds and the cardiac catheter-
isation laboratory), as well as underlying differences in clinical
decision making and hospital-speciﬁc protocols. Two hospitals
reported signiﬁcantly longer in-patient LOS for high-risk
patients, which may provide another priority area for quality
improvement.
The present study is subject to limitations with regard to the
representation of processes of care and patient outcomes, as
well as to potential confounding. Additional process data would
provide a clearer indication of the causes of observed variation in
costs and outcomes (e.g. ED and ward stafﬁng levels, in-patient
operating capacity, medication use, allied health and rehabilita-
tion service use and discharge referrals).
The routine collection of patient-reported outcome measures
(PROMs) would improve the reported outcomes.11 However, the
use of linked data informed patient outcomes after discharge,
which improves on the main in-hospital measure of outcome
(mortality),which has been criticised for its ‘low sensitivity (most
quality problems do not cause death) and low speciﬁcity (most
deaths do not reﬂect poor-quality care)’.12
Casemix adjustment was informed by a wide range of clinical
data, including pathology results, but the statistical analyses
would be improved if other diagnostic indicators, such as elec-
trocardiogram results, were available, as well as links to ambu-
lance data to inform pathways to the hospital. The ongoing
development of electronic patient records and costing systems
should inform more detailed casemix adjustment and process
analyses, and possibly PROMs, over time. Such data should
improve the sensitivity and speciﬁcity of the presented compar-
ative analyses to identify important areas of unwarranted varia-
tion in clinical practice, but the perfect should not become the
enemy of the good and the best available data at present should
be used to identify important areas of existing unwarranted
variation.
The identiﬁcation of important variation does not necessarily
mean that attempts to reduce variation will be a cost-effective
use of scarce resources.13 The estimation of ‘policy cost-
effectiveness’ incorporates the costs and effects of actions to
change the delivery of care, as well as the costs and beneﬁts of
improved quality of care. In areas in which important variation
is suspected, ACSQHC guidelines describe the conduct of a
thorough review of data sources, casemix, hospital structures
and resources, processes of care and professional issues to
inform subsequent actions to improve quality.6 Lilford et al. also
deﬁne an involved improvement process, comprising multiple
stages, as follows: (1) investigation of the causes of variation
from benchmark practice; (2) identiﬁcation of potential barriers
and facilitators to quality improvement; (3) decisions regarding
appropriate actions; (4) implementation of the deﬁned
improvements; and (5) post-implementation evaluation.3
These are not trivial processes, which emphasises the need for
careful consideration of both the importance of any observed
variation and the expected effectiveness of actions taken to
reduce variation and improve quality. As illustrated by the
present case study, the joint interpretation of variation in pro-
cesses of care, costs and outcomes informs discussions around
both aspects of policy cost-effectiveness. The potential beneﬁts
Table 5. Emergency department and in-patient length of stay
Statistically signiﬁcant differences are bolded. ED, emergency department; LOS, length of stay; circ., circulatory condition; weekend, weekend
presentation; weekday, weekday presentation; CI, conﬁdence interval
No. patients Mean LOS Mean LOS minus LOS at Hospital 2 (h; 95% CI)
Hospital 2 (h) Hospital 1 Hospital 3 Hospital 4
LOS in ED
All patients 7950 10.6 1.1 (0.5, 1.7) –4.4 (–5.0, –3.9) –0.6 (–1.2, 0.1)
Troponin positive, existing circ. 842 10.2 –1.2 (–2.7, 0.4) –4.6 (–6.0, –3.2) –2.4 (–3.9, –0.9)
Troponin positive, no existing circ. 216 9.5 1.1 (0.4, 1.8) –4.4 (–5.0, –3.9) –0.2 (–0.9, 0.5)
Troponin negative, existing circ. 1946 11.0 –0.2 (–1.7, 1.3) –4.6 (–6.0, –3.2) –2.4 (–3.9, –0.9)
Troponin negative, no existing circ. 4946 10.3 2.1 (1.1, 2.9) –4.4 (–5.0, –3.9) –0.2 (–0.9, 0.5)
In-patient LOS
All patients 7950 41.7 2.9 (–1.1, 6.9) 6.0 (2.3, 9.7) –4.5 (–8.4, –0.8)
Troponin positive, weekend 279 74.4 –14.8 (–30.9, 1.3) –1.7 (–17.4, 14.4) –18.0 (–34.2, –2.5)
Troponin positive, weekday 779 64.9 –6.7 (–22.9, 9.0) 1.4 (–14.4, 16.9) –13.8 (–29.4, 1.5)
Troponin negative, weekend 1632 37.6 2.6 (–1.7, 6.5) 6.1 (1.6, 10.1) –3.8 (–7.9, 0.1)
Troponin negative, weekday 5260 34.8 10.7 (5.6, 15.9) 9.2 (4.3, 13.8) 0.4 (–4.2, 5.0)
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of quality improvement at each hospital are informed by
analyses of costs and outcomes. The analyses of processes of
care identify speciﬁc areas of focus for quality improvement
along the clinical pathway, which may usefully inform the costs
and likelihood of beneﬁts of a quality improvement initiative.
The reported analysis of processes of care, costs and patient
outcomes could be applied to a wide range of clinical areas as
a form of screening to identify clinical areas and hospitals for
which further analysis and intervention is justiﬁed to diagnose
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